BioMarin Pharmaceutical BMRN reported first-quarter 2025 adjusted earnings per share of $1.13, which beat the Zacks Consensus ...

Palynziq is one of BioMarin’s most successfully marketed products. The company added $355 million from the PKU drug’s sales, indicating 17% year-over-year growth, driven by strong commercial ...

Pegvaliase, a phenylalanine (Phe)-metabolizing enzyme, is currently marketed under the brand name Palynziq ® to reduce blood Phe concentrations in adult patients with PKU who have uncontrolled ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) just the other day announced that it had achieved positive results from its phase 3 Pegasus trial using its drug Palynziq [pegvaliase] to treat patients ...

Discover BioMarin's Q1 2025 highlights: 15% revenue growth, VOXZOGO's 40% surge, and innovative R&D initiatives.

SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its ...

BioMarin (BMRN) Pharmaceutical announced that the Phase 3 PEGASUS trial evaluating Palynziq met its primary efficacy endpoint, demonstrating a statistically significant lowering in blood Phe ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) compared to diet alone in 55 adolescents aged 12-17 with ...

Biomarin Pharmaceutical Inc (BMRN) reports a robust 15% revenue increase and significant profitability expansion, while navigating global market dynamics and strategic investments.

SAN RAFAEL, Calif., April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ ® (pegvaliase-pqpz) met its primary ...